Disadaptive disorders in women: allopregnanolone, a sensitive steroid

REFERENCES

• Corpechot C, Collins BE, Carey MP, et al. Brain neurosteroids during the mouse oestrous cycle. Brain Res 1997;766:276–80
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Palumbo MA, de Micheroux AA, et al. Evidence for a role for the neurosteroid allopregnanolone in the modulation of reproductive function in female rats. Eur J Endocrinol 1995;133: 375–80
   PubMed Web of Science ®Google Scholar
• Fadalti M, Petraglia F, Luisi S, et al. Changes of serum allopregnanolone levels in the first 2 years of life and during pubertal development. Pediatr Res 1999;46:323–7
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Petraglia F, Bernardi F, et al. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Gun Endocrinol Metab 1998;83:2099–103
   PubMed Web of Science ®Google Scholar
• van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology (Berl) 2003; 165:97–110
   PubMed Web of Science ®Google Scholar
• Bernardi F, Lanzone A, Cento RIVL et al. Allo-pregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur J Endocrinol 2000;142:466–71
   PubMed Web of Science ®Google Scholar
• Stoffel-Wagner B. Neurosteroid biosynthesis in the human brain and its clinical implications. Ann N Y Acad Sci 2003;1007:64–78
   PubMed Web of Science ®Google Scholar
• Holzbauer M, Birmingham MK, De Nicola AF, Oliver JT. In vivo secretion of 3a-hydroxy-5a-pregnan-20-one, a potent anaesthetic steroid, by the adrenal gland of the rat. J Steroid Biochem 1985;22:97–102
   PubMedGoogle Scholar
• Purdy RH, Morrow AL, Moore PH Jr, Paul SM. Stress-induced elevations of y-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991;88:4553–7
   PubMed Web of Science ®Google Scholar
• Barbaccia ML, Roscetti G, Trabucchi M, et al. Time-dependent changes in rat brain neuroactive steroid concentrations and GABAA receptor func-tion after acute stress. Neuroendocrinology 1996;63: 166–72
   PubMed Web of Science ®Google Scholar
• Barbaccia ML, Serra M, Purdy RH, Biggio G. Stress and neuroactive steroids. Int Rev Neurobiol 2001;46:243–72
   PubMed Web of Science ®Google Scholar
• Patchev VK, Montkowski A, Rouskova D, et al. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine con-sequences of adverse early life events. J Clin Invest 1997;99:962–6
   PubMedGoogle Scholar
• Picazo O, Fernandez-Guasti A. Anti-anxiety effects of progesterone and some of its reduced metabolites: an evaluation using the burying behavior test. Brain Res 1995;680:135–41
   PubMedGoogle Scholar
• Brot MD, Akwa Y, Purdy RH, et al. The anxiolytic-like effects of the neurosteroid allopreg-nanolone: interactions with GABA(A) receptors. Eur J Pharmacol 1997;325:1–7
   PubMed Web of Science ®Google Scholar
• Guidotti A, Dong E, Matsumoto K, et al. The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5a-dihydro-progesterone in psychiatric disorders. Brain Res Brain Res Rev 2001;37:110–15
   PubMed Web of Science ®Google Scholar
• Pinna G, Dong E, Matsumoto K, et al. In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. Proc Natl Acad Sci USA 2003;100: 2035–40
   PubMed Web of Science ®Google Scholar
• Serra M, Pisu MG, Littera M, et al. Social isolation-induced decreases in both the abundance of neuroactive steroids and GABA(A) receptor func-tion in rat brain. J Neurochem 2000;75:732–40
   PubMed Web of Science ®Google Scholar
• Semeniuk L, LeMelledo JM, Shangri GS. Neuroac-tive steroid levels in patients with generalized anxiety disorder. J Neuropsychiatry Clin Neurosc-i 2001;13:396–8
   Google Scholar
• Heydari B, Le Melledo JM. Low pregnenolone sulphate plasma concentrations in patients with generalized social phobia. Psychol Med 2002;32: 929–33
   PubMed Web of Science ®Google Scholar
• Brambilla F, Biggio G, Pisu MG, et al. Neurosteroid secretion in panic disorder. Psychiatry Res 2003;118: 107–16
   PubMed Web of Science ®Google Scholar
• Frye CA, Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm Behav 2002;41:306–15
   PubMed Web of Science ®Google Scholar
• Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3a-hydroxy-5a-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 2000;67: 137–43
   Google Scholar
• Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95:3239–44
   PubMed Web of Science ®Google Scholar
• Romeo E, Stroehle A, Spalletta G, et al. Effects of antidepressant treatment on neuroactive steroids in maj or depression. Am J Psychiatry 1998;155:910–13
   PubMed Web of Science ®Google Scholar
• Uzunov DP, Cooper TB, Costa E, Guidotti A. Fluoxetine elicited changes in brain neurosteroid content measured by negative ion mass fragmento-graphy. Proc Natl Acad Sci USA 1996;93:12599–604
   PubMed Web of Science ®Google Scholar
• Griffin LD, Mellon SH. Selective serotonin reup-take inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 1999;96:13512–17
   PubMed Web of Science ®Google Scholar
• Backstrom T, Andersson A, Andree L, et al. Pathogenesis in menstrual cycle-linked CNS dis-orders. Ann N Y Acad Sci 2003;1007:42–53
   PubMed Web of Science ®Google Scholar
• Monteleone P, Luisi S, Tonetti A, et al. Allopreg-nanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000;142:269–73
   PubMed Web of Science ®Google Scholar
• Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in wo-men with premenstrual syndrome. Obstet Gynecol 1997;90:709–14
   PubMed Web of Science ®Google Scholar
• Bicikova M, Dibbelt L, Hill M, et al. Allopregna-nolone in women with premenstrual syndrome. Horm Metab Res 1998;30:227–30
   PubMed Web of Science ®Google Scholar
• Bicikova M, Putz Z, Hill M, et al. Serum levels of neurosteroid allopregnanolone in patients with premenstrual syndrome and patients after thyroi-dectomy. Endocr Regul 1998;32:87–92
   PubMedGoogle Scholar
• Lombardi I, Luisi S, Quirici B, et al. Adrenal response to adrenocorticotropic hormone stimula-tion in patients with premenstrual syndrome. Gynecol Endocrinol 2004;18:79–87
   PubMed Web of Science ®Google Scholar
• Wang M, Seippel L, Purdy RH, Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5a-pregnane-3,20-dione and 3a-hydroxy-5a-preg-nan-20-one. J Clin Endocrinol Metab 1996;81:1076–82
   PubMed Web of Science ®Google Scholar
• Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility, 5th edn. Baltimore, MD: Williams and Wilkins, 1995
   Google Scholar
• Kaye WH, Berrettini WH, Gwirtsman HE, et al. Contribution of CNS neuropeptide (NPY, CRH, and fl-endorphin) alterations to psychophysiological abnormalities in anorexia nervosa. Psychopharmacol Bull 1989;25:433–8
   PubMedGoogle Scholar
• Monteleone P, Luisi M, Colurcio B, et al. Plasma levels of neuroactive steroids are increased in untreated women with anorexia nervosa or bulimia nervosa. Psychosom Med 2001;63:62–8
   PubMed Web of Science ®Google Scholar
• Monteleone P, Luisi M, De Filippis G, et al. Circulating levels of neuroactive steroids in patients with binge eating disorder: a comparison with nonobese healthy controls and non-binge eating obese subjects. Int J Eat Disord 2003;34:432–40
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Luisi M, Malavasi B, et al. Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects. Eur J Endocrinol 2002; 146:347–56
   PubMed Web of Science ®Google Scholar
• Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry 2003;44:234–46
   Google Scholar
• Smith R, Thomson M. Neuroendocrinology of the hypothalamo—pituitary—adrenal axis in pregnancy and the puerperium. Clin Endocrinol Metab 1991;5: 167–86
   Google Scholar
• Tulchinsky D, Hobel CJ, Yeager EM. Plasma estrone, estradiol, estriol, progesterone and 17-hydroxyprogesterone in human pregnancy. Am J Obstet Gynecol 1972;112: 1095–100
   Google Scholar
• Heidrich A, Schleyer M, Spingler H, et al. Postpartum blues: relationship between notprotein bound steroid hormones in plasma and postpartum mood changes. J Affect Disord 1994;30:93–8
   PubMed Web of Science ®Google Scholar
• Gordon JH, Perry KO. Pre- and postsynaptic neurochemical alterations following estrogen-in-duced striatal dopamine hypo- and hyper-sensitivity. Brain Res Bull 1983;10:425–8
   PubMed Web of Science ®Google Scholar
• Wieck A, Kumar R, Hirst AD, et al. Increased sensitivity of dopamine receptors and recurrence of affective psychosis after childbirth. Br Med J 1991; 303:613–16
   PubMed Web of Science ®Google Scholar
• Bosse R, Rivest R, Dipaolo T. Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res 1997;46:343–6
   PubMedGoogle Scholar
• Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depres-sion. Lancet 1996;347:930–3
   PubMed Web of Science ®Google Scholar
• Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311–22
   PubMed Web of Science ®Google Scholar
• Costa AM, Spence KT, Smith SS, Ffrench-Mullen JM. Withdrawal from the endogenous steroid progesterone results in GABAA currents insensitive to benzodiazepine modulation in rat CA1 hippo-campus. J Neurophysiol 1995;74: 464–9
   Google Scholar
• Nicosia A, Giardina L, Di Leo F, et al. Long-lasting behavioral changes induced by pre- or neonatal exposure to diazepam in rats. Eur J Pharmacol 2003; 469:103–9
   PubMed Web of Science ®Google Scholar
• Nappi RE, Petraglia F, Luisi S, et al. Serum allopregnanolone in women with postpartum 'blues'. Obstet Gynecol 2001;97:77–80
   PubMed Web of Science ®Google Scholar
• Majewska MD, Ford-Rice R, Falkay G. Pregnancy-induced alterations of GABAA receptor sensitivity in maternal brain: an antecedent of post-partum 'blues'? Brain Res 1989;482:397–401
   PubMed Web of Science ®Google Scholar
• Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995;7:171–7
   Google Scholar
• Harris B, Lovett L, Newcombe KG, et al. Maternity blues and major endocrine changes: Cardiff puerp-eral mood and hormone study II. Br Med J 1994;308:949–53
   PubMed Web of Science ®Google Scholar
• O'Hara MW, Schlechte JA, Lewis DA, Wright EJ. Prospective study of postpartum blues. Biologic and psychosocial factors. Arch Gen Psychiatry 1991;48: 801–6
   PubMed Web of Science ®Google Scholar
• Abou-Saleh MT, Ghubash R, Karim L, et al. Hormonal aspects of postpartum depression. Psycho-neuroendocrinology 1998;23:465–75
   PubMed Web of Science ®Google Scholar
• Luisi S, Petraglia F, Benedetto C, et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab 2000; 85:2429–33
   PubMed Web of Science ®Google Scholar
• Montgomery JC, Appleby L, Brincat M, et al. Effect of oestrogen and testosterone implants on psycho-logical disorders in the climacteric. Lancet 1987;1: 297–9
   PubMed Web of Science ®Google Scholar
• Rasgon NL, Altshuler LL, Fairbanks LA, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal wo-men. J Clin Psychiatry 2002;63\(Suppl. 7):45–8
   Google Scholar
• Robinson GE. Psychotic and mood disorders associated with the perimenopausal period: epide-miology, aetiology and management. CNS Drugs 2001;15:175–84
   PubMed Web of Science ®Google Scholar
• Payne JL. The role of estrogen in mood disorders in women. Int Rev Psychiatry 2003;15:280–90
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Petraglia F, Facchinetti F, et al. Steroid replacement increases fl-endorphin and fi-lipotropin plasma levels in postmenopausal women. Gynecol Obstet Invest 1988;26:153–9
   PubMed Web of Science ®Google Scholar
• Bernardi F, Pluchino N, Stomati M, et al. CNS: sex steroids and SERMs. Ann N Y Acad Sci 2003;997: 378–88
   PubMed Web of Science ®Google Scholar
• Stomati M, Bernardi F, Luisi S, et al. Conjugated equine estrogens, estrone sulphate and estradiol valerate oral administration in ovariectomized rats: effects on central and peripheral allopregnanolone and fl-endorphin. Maturitas 2002;43:195–206
   PubMed Web of Science ®Google Scholar
• Bernardi F, Salvestroni C, Casarosa E, et al. Aging is associated with changes in allopregnanolone con-centrations in brain, endocrine glands and serum in male rats. Eur J Endocrinol 1998;138:316–21
   PubMedGoogle Scholar
• Bernardi F, Pieri M, Stomati M, et al. Effect of different hormonal replacement therapies on circu-lating allopregnanolone and dehydroepiandro-sterone levels in postmenopausal women. Gynecol Endocrinol 2003;17:65–77
   PubMed Web of Science ®Google Scholar